STOCK TITAN

Anixa Biosciences Inc - ANIX STOCK NEWS

Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.

Anixa Biosciences Inc (NASDAQ: ANIX) is a clinical-stage biotechnology company advancing novel immunotherapies and vaccines for cancer treatment and prevention. This page provides investors and industry stakeholders with timely updates on ANIX’s oncology innovations, including clinical trial progress, strategic collaborations, and therapeutic breakthroughs.

Access the latest press releases and news covering ANIX’s CAR-T programs targeting ovarian cancer, vaccine development for breast cancer, and partnerships with leading research institutions. Content spans earnings updates, clinical milestones, patent developments, and analysis of emerging technologies like CER-T (chimeric endocrine receptor T-cell) therapy.

Bookmark this page to stay informed about ANIX’s progress in addressing high-need oncology areas through its focused pipeline. Check regularly for authoritative updates on trials, regulatory filings, and scientific advancements directly from the company and verified sources.

Rhea-AI Summary

Anixa Biosciences, Inc. (NASDAQ: ANIX) will present a company update at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will cover Anixa's recent achievements, including the initiation of a clinical trial for its CAR-T based ovarian cancer treatment. The on-demand presentation starts at 7:00 a.m. ET on May 24, 2022, and can be accessed through a provided webcast link. A replay will be available for 90 days. Anixa focuses on cancer therapies and infectious diseases, collaborating with top medical institutions to develop innovative treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.34%
Tags
conferences
-
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced a presentation of its breast cancer vaccine trial at the ASCO Annual Meeting on June 3-7, 2022. The presentation, led by Dr. George Thomas Budd of Cleveland Clinic, focuses on a Phase 1 trial of an alpha-Lactalbumin vaccine for patients with operable triple-negative breast cancer (TNBC). With TNBC being a significant challenge in oncology, accounting for a high percentage of breast cancer deaths, Anixa’s approach targets proteins unique to this cancer type. The vaccine aims to activate the immune system for early tumor prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
Rhea-AI Summary

On April 6, 2022, Anixa Biosciences (NASDAQ: ANIX) announced that Dr. José Conejo-Garcia will present its ovarian cancer CAR-T technology at The 4th International Workshop on CAR-T on April 29, 2022. He will chair a panel discussing Chimeric Endocrine Receptor T-cell (CER-T) technology for treating ovarian cancer. A Phase 1 clinical trial using this innovative therapy has recently begun at Moffitt Cancer Center. Anixa holds an exclusive worldwide license for this technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
none
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) has launched a Phase 1 trial for its innovative chimeric endocrine receptor T-cell (CER-T) therapy targeting ovarian cancer at Moffitt Cancer Center. This trial aims to assess the safety and effectiveness of CER-T therapy, which uniquely targets the follicle stimulating hormone receptor (FSHR), exclusively expressed on ovarian cells. With an exclusive license for this technology developed at the Wistar Institute, Anixa partners with leading scientists to enhance treatment options for recurrent, chemo-resistant ovarian cancer, potentially revolutionizing therapy for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the 2022 Virtual Growth Conference hosted by M-Vest from March 28-30, 2022. The presentation will be led by Mike Catelani, the Chief Operating Officer and Chief Financial Officer, who will provide an overview of the company's business and program updates. Anixa focuses on developing cancer treatments and vaccines, including an innovative CAR-T immunotherapy and vaccines targeting triple negative breast cancer and ovarian cancer. For more details, visit www.anixa.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
conferences
-
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) has received a Decision to Grant a patent from the Japanese Patent Office for its ovarian cancer vaccine technology, developed at Cleveland Clinic. This vaccine targets the anti-Müllerian hormone receptor 2 (AMHR2-ED), potentially preventing ovarian cancer, particularly in post-menopausal women. Preclinical studies are ongoing at the National Cancer Institute (NCI), with promising data previously published. Anixa's innovative approach aims to provide a preventative measure against one of the most aggressive cancers, enhancing its therapeutic portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced a significant breakthrough with its partner MolGenie GmbH in developing a new compound that shows greater potency than nirmatrelvir, the primary component of Pfizer's COVID-19 treatment, PAXLOVID. The compound targets the main protease (Mpro) of SARS-CoV-2, which is preserved across various virus variants. Anixa's compounds are undergoing further testing, including cellular assays and animal studies, with potential for improved oral therapies against COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none
-
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) is set to participate in two significant investor conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5-7, 2022, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Dr. Amit Kumar will address a panel on cancer vaccines on January 7 at 2:00 pm ET. Investors can request 1x1 meetings during both events. Anixa is focused on innovative cancer therapies and COVID-19 treatments, including a vaccine for triple negative breast cancer (TNBC).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences
-
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) has partnered with MolGenie to analyze compounds aimed at treating COVID-19. Recent findings suggest these compounds could be effective against the Omicron and Delta variants of SARS-CoV-2. The focus is on developing inexpensive, orally-administered therapies that can inhibit the virus’s main protease (Mpro). The compounds have shown promising efficacy and potency in initial testing. Anixa continues to adapt its strategy in response to emerging COVID-19 variants to support global health efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
covid-19
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) has started dosing patients in a Phase 1 study of a vaccine aimed at preventing triple-negative breast cancer, a particularly aggressive cancer type. Conducted in partnership with Cleveland Clinic, the study is funded by the U.S. Department of Defense and will involve 18 to 24 patients at high risk for recurrence. Participants will receive three doses of the vaccine over six weeks. The study aims to assess the maximum tolerated dose and immune response, with completion expected by Q3 2022. The vaccine uses a unique approach targeting specific proteins associated with breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
none
Anixa Biosciences Inc

Nasdaq:ANIX

ANIX Rankings

ANIX Stock Data

86.88M
29.87M
5.29%
18.3%
1.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN JOSE